Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up

• Published in: Journal of the American Academy of Dermatology Vol. 67; no. 4; pp. 623 - 629
• Main Authors: Reguiai, Ziad, Tabary, Thierry, Maizières, Michael, Bernard, Philippe
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.10.2012; Elsevier
• Subjects: Adolescent; Adult; Aged; anti-desmoglein autoantibodies; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Autoantibodies - blood; Biological and medical sciences; Bullous diseases of the skin; Child; Child, Preschool; Dermatology; Desmoglein 3 - immunology; Drug Therapy, Combination - methods; enzyme-linked immunosorbent assay; Female; Follow-Up Studies; Humans; Immunologic Factors - administration & dosage; Immunosuppressive Agents - administration & dosage; Male; Medical sciences; Middle Aged; Pemphigus - drug therapy; Pemphigus - immunology; pemphigus foliaceus; pemphigus vulgaris; Retrospective Studies; Rituximab; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult; pemphigus foliaceus; anti-desmoglein autoantibodies; PV; IVIg; CR; pemphigus vulgaris; PF; enzyme-linked immunosorbent assay; RTX; DSG1; DSG3; rituximab; ELISA; intravenous immunoglobulins; desmoglein-1; desmoglein-3; complete remission; Bullous dermatosis; Antineoplastic agent; Immunomodulator; Immunopathology; Skin disease; Treatment; Dermatology; Pemphigus; Rituximab; Autoimmune disease; Immunosuppressive agent; Long term

Rituximab (RTX) has been shown to be effective and safe for short-term treatment of severe pemphigus. Its long-term results remain unknown. We sought to evaluate long-term RTX efficacy and safety in comparison with classic immunosuppressants for the treatment of severe pemphigus. This retrospective...